ALDH7A1 and fragile X syndrome: It provides a comprehensive overview of both synthetic and natural PDE inhibitors as emerging therapeutic strategies and emphasizes the underlying mechanistic pathways (including oxidative stress, synaptic plasticity and neuroinflammation mediated through increased cAMP and cGMP signaling) that lead to improved behavioral outcomes in ASD and FXS.